CTLA4 and metastatic melanoma: As a breakthrough approach for metastatic melanoma, immunotherapy is based on the activation of the anticancer endogenous immune system, whose representative immune checkpoints are cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) (Marzagalli et al., 2019).